Two hyperbaric chambers can look almost identical from the outside and produce entirely different biology on the inside. The variable that matters is pressure — and the gap between a wellness-grade soft shell and a clinical-grade hard chamber is wider than most patients are ever told.
Hyperbaric oxygen therapy (Hyperbaric Oxygen Therapy) is among the most-studied modalities in longevity medicine. The peer-reviewed evidence for stem-cell mobilization, telomere lengthening, neovascularization and reduced senescent-cell burden is real — but it lives almost exclusively at pressures of 2.0 atmospheres absolute (ATA) and above. Soft-shell chambers cannot reach those pressures. They are mechanically incapable of it.
That single fact is the most important thing to understand before you spend money on Hyperbaric Oxygen Therapy.
What pressure actually does to oxygen
At sea level, your red blood cells carry roughly 97% of the oxygen in your bloodstream. Plasma — the liquid part — carries almost none. Oxygen is poorly soluble in water at one atmosphere.
Increase the surrounding pressure and the physics changes. Henry's law dictates that gas solubility rises in proportion to partial pressure. At 2.0 ATA on 100% oxygen, the partial pressure of oxygen jumps roughly tenfold. Oxygen is forced into solution in plasma, cerebrospinal fluid, and lymph — fluids that normally service your tissues with very little oxygen of their own.
That dissolved oxygen reaches places your red blood cells struggle to perfuse: the deep capillary beds, post-injury tissue, the white matter of the brain. It also activates a paradoxical response — the so-called hyperoxic-hypoxic paradox — where the body reads the cycling between high-oxygen and normal-oxygen states as a regenerative signal, triggering stem-cell release, mitochondrial biogenesis, and telomere protection.
Sixty sessions at 2.0 ATA produced a ~20% increase in telomere length and a ~30% drop in senescent T-cells in healthy older adults — with no medication.
— Hachmo et al., Aging (2020)
Why a 1.3 ATA "mild" chamber can't reach the same biology
Soft-sided chambers — the inflatable units sold for home use and at many wellness studios — max out around 1.3 ATA. At that pressure on room air, the increase in dissolved oxygen is real but small. It can support general circulation and may produce a measurable subjective effect after a session. What it cannot do is produce the partial-pressure thresholds the longevity and neuro literature is built on.
The clinical effects most patients are actually paying for — stem-cell mobilization, durable cognitive benefit, post-injury tissue regeneration — require sustained exposure at 2.0 ATA or higher, on 100% oxygen, in a hard-shell chamber, across clustered sessions. One-off sessions at any pressure are essentially irrelevant for those endpoints.
The clinical comparison, side by side
| Soft-shell 'mild' | Hard-chamber clinical | |
|---|---|---|
| Max pressure | ~1.3 ATA | 2.0–2.4 ATA |
| Oxygen source | Concentrated room air (~95%) | 100% medical oxygen |
| Stem cell mobilization | Minimal | Documented in peer-reviewed trials |
| Telomere effects | Not demonstrated | ~20% length increase across 60 sessions |
| Physician oversight | Often technician-only | Standing physician orders |
| Best use case | Casual recovery, light wellness | Longevity, recovery, cognition, post-injury |
What "clustered" actually means
Dosing is the second variable patients underestimate. Across the longevity literature, the effects scale with cluster density, not total session count. Sixty sessions delivered across two years will not produce the biology that sixty sessions delivered across twelve weeks will. The body needs the cycling — the on-off oxygen pulse, repeated frequently — to read it as a regenerative signal.
At BioHaus, our standard Deep Longevity arc is a 60-session protocol delivered across roughly twelve to fourteen weeks, with biomarker checkpoints at session 1, 30, and 60, and a qEEG re-baseline at completion. Recovery and post-injury protocols are shorter — typically 8 to 20 sessions — but still tightly clustered.
What we recommend before starting
Before any Hyperbaric Oxygen Therapy arc, we run a physician intake to screen for the small set of contraindications that genuinely matter (untreated pneumothorax, certain ear and sinus conditions, specific chemotherapy agents, uncontrolled seizure disorder), establish a biomarker baseline, and confirm the goal of the protocol. Hyperbaric Oxygen Therapy is not a symptom treatment. It is a clinical tool with a specific mechanism — and it works best when matched to a specific question.
Pressure is not a marketing variable. It is the variable.
If you're considering Hyperbaric Oxygen Therapy, the questions worth asking are simple. What pressure? What oxygen source? Who signs the order? How is the dose clustered? Anything that doesn't answer those four with conviction isn't Hyperbaric Oxygen Therapy in the clinical sense. It's a chamber.
